The launch of ORLADEYO® in Italy represents a significant milestone for BioCryst Pharmaceuticals, as it is the first oral, once-daily therapy for HAE prevention available in the country. This approval by AIFA not only expands the product's market but also strengthens the company's revenue potential in Europe. Given the novelty of the treatment and its importance for HAE patients, this development is likely to have a positive impact on BCRX's stock in the short term.